Exposure 0 8 0 8 O
to 9 11 9 11 O
any 12 15 12 15 O
investigational 16 31 16 31 B-treatment
drug 32 36 32 36 I-treatment
or 37 39 37 39 O
procedure 40 49 40 49 O
with 50 54 50 54 O
1 55 56 55 56 B-upper_bound
month 57 62 57 62 I-upper_bound
prior 63 68 63 68 I-upper_bound
to 69 71 69 71 O
study 72 77 72 77 O
entry 78 83 78 83 O
or 84 86 84 86 O
enrollment 87 97 87 97 O
in 98 100 98 100 O
concurrent 101 111 101 111 O
study 112 117 112 117 O
which 118 123 118 123 O
may 124 127 124 127 O
interfere 128 137 128 137 O
with 138 142 138 142 O
interpretation 143 157 143 157 O
of 158 160 158 160 O
study 161 166 161 166 O
results 167 174 167 174 O

Hepatitis 0 9 175 184 B-chronic_disease
A 10 11 185 186 I-chronic_disease
history 12 19 187 194 O

Lactating 0 9 195 204 O
Females 10 17 205 212 B-gender

Patients 0 8 213 221 O
positive 9 17 222 230 O
for 18 21 231 234 O
Hepatitis 22 31 235 244 B-chronic_disease

Prior 0 5 245 250 O
Diagnosis 6 15 251 260 O
of 16 18 261 263 O
moderate 19 27 264 272 B-chronic_disease
to 28 30 273 275 I-chronic_disease
severe 31 37 276 282 I-chronic_disease
COPD 38 42 283 287 I-chronic_disease

Subjects 0 8 288 296 O
on 9 11 297 299 O
chronic 12 19 300 307 B-treatment
immunosuppressive 20 37 308 325 I-treatment
or 38 40 326 328 O
chemotherapeutic 41 57 329 345 B-treatment
medications 58 69 346 357 I-treatment

